Analyst Price Targets — XLO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 21, 2022 6:21 am | — | Chardan Capital | $98.00 | $27.58 | Benzinga | Chardan Capital Initiates Coverage On Xilio Therapeutics with Buy Rating, Announces Price Target of $7 |
Latest News for XLO
WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2026, the company granted non-qualified stock options to purchase 107,060 shares of its common stock to three new employees under Xilio Therapeutics' 2022…
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Ben Harshbarger as chief legal officer.
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $2.52 per share a year ago.
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XLO.
U.S. House Trading
No House trades found for XLO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.